First dosing of Tacrolimus Inhalation Powder initiates development program for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection Phase 1 topline data indicates safety of single doses of Voriconazole Inhalation Powder up to 80 mg/dose in

AUSTIN, Texas --(BUSINESS WIRE)--Jun. 18, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the U.S.

Maintains clinical progress with lead programs, Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder Thin Film Freezing platform technology employed in numerous partnership programs for vaccine and anti-viral applications Conference call and live webcast scheduled for Thursday, May 14,